Biosimilars are FDA-approved biologic medications built to be highly similar to an already-approved reference biologic, with no clinically meaningful difference in safety, purity, or effectiveness. Lantus (insulin glargine, Sanofi), Humira (adalimumab, AbbVie), and Stelara (ustekinumab, Janssen) are three of the most-prescribed reference biologics in the United States, and each now faces biosimilar competition: Semglee and Rezvoglar for Lantus, 10 adalimumab biosimilars for Humira, and eight ustekinumab biosimilars for Stelara. Unlike a generic drug, which is an exact chemical copy of a small-molecule medication, a biosimilar is manufactured from living cells and can never be a perfect molecular match to its reference product, which is why the FDA regulates biosimilars through a distinct approval pathway under the Biologics Price Competition and Innovation Act.
Federal law creates two tiers of biosimilar approval that matter directly for cost and access in 2026. A standard biosimilar requires a new prescription from the prescriber every time a patient wants to switch products. An interchangeable biosimilar clears a higher FDA evidentiary bar, typically including switching studies that show no added risk from alternating between the biosimilar and the reference product, and once designated interchangeable, a pharmacist can substitute it at the counter the same way pharmacists substitute generic pills for brand-name tablets, without calling the prescriber first. Semglee (insulin glargine-yfgn) was the first interchangeable biosimilar ever approved in the United States in 2021, followed by Rezvoglar in 2022. Wezlana became the first interchangeable ustekinumab biosimilar for Stelara in 2023. Basaglar, by contrast, was approved through an older regulatory pathway before the biosimilar framework existed and is not designated as interchangeable, so a new prescription is required to switch to or from it.
Insurance and Medicare treat biosimilars and their reference biologics under the same coverage rules that apply to the drug class overall. Medicare Part D caps out-of-pocket insulin costs, brand or biosimilar, at $35 per month in 2026 under the Inflation Reduction Act of 2022, and every Part D drug combined is capped at $2,100 per year out of pocket. Stelara and Enbrel are also two of the ten drugs in the first round of Medicare drug price negotiation, with negotiated Maximum Fair Prices effective January 1, 2026, discussed further below. Patients considering a switch should also check whether Medicaid income limits or a plan's formulary tier placement changes their specific copay, since state Medicaid programs frequently place a preferred biosimilar on a lower cost-sharing tier than the reference brand.
What Biosimilar vs. Biologic Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same biosimilar vs. biologic can cost many times more at a hospital than at your local pharmacy:
2026 Biosimilar vs. Biologic Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Medicare ASP rate (Part B, clinical/DME administration) | ~$0.14/unit (J1815); pump supply billed per 50 units (J1817) | Rare pathway; applies only when insulin is administered in a clinic, hospital, or through a covered insulin pump. Most patients are billed under Part D instead. |
| Pharmacy counter (retail, cash, 2026) | $74 - $150/month (biosimilar) vs. $274 - $400/month (brand Lantus) | Cash price without insurance for a 30-day insulin glargine supply. Humira and Stelara biosimilar cash prices run 55-90% below their brand list prices; see the pharmacy comparison table below. |
| Medicare Part D (2026) | $35/month cap on insulin (brand or biosimilar); $2,100/year cap on all Part D drugs combined | The IRA insulin cap applies identically to Lantus, Basaglar, Semglee, and Rezvoglar. Stelara and Enbrel are billed at their negotiated Maximum Fair Price starting 2026-01-01. |
| Commercial insurance | $10 - $100/month after prior authorization, depending on formulary tier | Many commercial plans place the interchangeable biosimilar on a lower formulary tier than the brand to steer utilization toward the cheaper option. |
| Medicaid | $1 - $4/prescription, with prior authorization | State Medicaid programs commonly prefer the biosimilar on their preferred drug list; check your state's Medicaid income limits and formulary before filling. |
Prices reflect 2026 GoodRx and pharmacy survey data plus CMS Part D benefit parameters. Formulary tier placement and prior authorization requirements vary by plan.
Source: CMS Medicare Part D 2026 benefit design, GoodRx, manufacturer list prices
Why Hospitals Charge So Much
Hospitals acquire insulin and biologic drugs at steep discounts through group purchasing organizations, 340B pricing, and direct manufacturer contracts, yet bill patients at the chargemaster rate, which can be set at or above the undiscounted list price. A partial vial of insulin that costs a hospital pharmacy a few dollars can appear on an itemized bill at $500 or more once nursing administration fees and per-dose handling charges are layered on top. Infused monoclonal antibody biologics like Stelara's intravenous induction dose show a far wider gap, sometimes appearing on hospital bills at $8,000 to $12,000 for a single infusion even when the acquisition cost under 340B is a fraction of that.
Biologics administered in a clinic, infusion center, or hospital outpatient department are billed under Medicare Part B rather than Part D, using HCPCS J-codes such as J1815 for injected insulin and J1817 for insulin delivered through a covered pump. Adalimumab uses J0139, and ustekinumab uses J3357 (subcutaneous) or J3358 (intravenous). When a biologic is billed under Part B, the 2026 Part B deductible of $283 and the standard 20 percent coinsurance apply before Medicare pays its share, which is why a single expensive infusion can generate a large out-of-pocket bill even for Medicare beneficiaries.
Coding errors compound the markup problem for biosimilars specifically. A biosimilar can share a payer's product-specific J-code or be billed under a miscellaneous unclassified code (like J3590) if the payer's system has not updated its formulary, which can trigger claim denials or a re-bill at the reference-brand rate. Patients who see an unexpectedly high biologic charge should request an itemized bill with the National Drug Code and HCPCS code and confirm the code matches the specific biosimilar or brand product that was actually dispensed.
HCPCS J-Codes: What Appears on Your Bill
These HCPCS Level II J-codes apply when insulin or a biologic is administered in a clinical setting and billed under Medicare Part B, rather than self-injected at home under Part D.
HCPCS J-codes for Biosimilar vs. Biologic| Code | Description | What to look for |
|---|
| J1815 | Injection, insulin, per 5 units (any insulin type, provider-administered) | Used for clinic or hospital-administered insulin doses. Verify the unit count on your EOB matches the actual dose given. |
| J1817 | Insulin for administration through DME (durable medical equipment, e.g. an insulin pump), per 50 units | Applies when insulin is dispensed alongside a Medicare-covered insulin pump under Part B rather than the pharmacy benefit. |
Most patients never see these codes because self-injected insulin at home is billed under Part D, not Part B. They matter mainly for hospital, clinic, or insulin-pump billing disputes.
Source: CMS HCPCS Level II code set 2025-2026
Patient Assistance Programs
Manufacturers of both reference biologics and biosimilars run patient assistance programs, and a switch to a biosimilar does not eliminate access to financial help. Sanofi, Eli Lilly, and the biosimilar manufacturers each operate a program, and eligibility differs sharply between an income-based patient assistance program and a commercial-insurance-only savings card.
Patient assistance programs for Biosimilar vs. Biologic| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Sanofi Patient Connection (Lantus) | Free Lantus for uninsured patients with household income at or below 400% FPL; Medicaid denial documentation required first | sanofipatientconnection.com |
| Lilly Insulin Value Program (Basaglar) | $35 for a 30-day supply, no income requirement, for commercially insured or uninsured patients; not available to Medicare or Medicaid enrollees | insulinaffordability.com |
| Viatris Advocate (Semglee) | Copay support for commercially insured patients on Semglee; contact the program for current uninsured-patient options | viatrisadvocate.com |
| myAbbVie Assist (Humira, reference biologic) | Free Humira for eligible uninsured patients at or below 600% FPL; closing to new applicants July 1, 2026 | abbvieaccess.com/patient-assistance |
| NeedyMeds Drug Discount Card and PAP Directory | Free directory of biosimilar and biologic manufacturer PAPs, copay cards, and pharmacy discounts | needymeds.org |
A manufacturer coupon or commercial savings card cannot be used by anyone enrolled in Medicare, Medicaid, TRICARE, or VA benefits under the federal anti-kickback statute (42 U.S.C. Section 1320a-7b). Patients with government insurance should apply for the income-based patient assistance program instead, such as Sanofi Patient Connection for Lantus, JJPAF for Stelara, or the state Medicaid formulary's preferred biosimilar, which typically carries only a $1 to $4 copay.
Source: Sanofi Patient Connection, Lilly Insulin Value Program, Viatris Advocate, AbbVie Patient Access, NeedyMeds.org
Medicare Part D Coverage for Biosimilar vs. Biologic
Medicare Part D caps out-of-pocket insulin costs at $35 per 30-day supply in 2026 under the Inflation Reduction Act of 2022, and this cap applies equally whether the pharmacy dispenses brand Lantus, Basaglar, Semglee, or Rezvoglar. No income test applies to the $35 insulin cap; it is a flat statutory limit for every Medicare Part D enrollee. Separately, every Part D drug combined, including biologics like Humira and Stelara, is capped at $2,100 in total annual out-of-pocket spending, after which the beneficiary pays $0 for the rest of the calendar year.
Formulary tier placement determines what a Part D enrollee actually pays before hitting either cap. CMS requires Part D plans to include biosimilar alternatives when they exist, but plans set their own tier for each product. A biosimilar placed on a preferred generic tier can carry a $0 to $10 copay, while the reference brand on a non-preferred tier can carry 25 to 40 percent coinsurance until the beneficiary reaches the annual cap. Patients who are clinically stable on a reference biologic and whose plan removes it from a preferred tier mid-year can request a formulary exception based on medical necessity.
Medicare beneficiaries with limited income may also qualify for the Low-Income Subsidy, also called Extra Help, which caps 2026 cost-sharing at $4.90 for generics and biosimilars and $11.20 for brand-name biologics per covered drug, well below the standard $35 insulin cap or the coinsurance a non-subsidized enrollee would pay for Humira or Stelara.
Common Biosimilar vs. Biologic Billing Errors
Biosimilar and biologic billing generates a disproportionate share of pharmacy claim errors. Check for these issues before paying a bill that seems higher than expected:
- The $35 Medicare Part D insulin cap not applied to a biosimilar, only to the brand, or vice versa. The cap applies to every FDA-approved insulin product identically in 2026; call your Part D plan if you are charged more.
- A pharmacist substituted an interchangeable biosimilar without documenting it on your prescription record, causing your insurer's claims system to flag a mismatch between the prescribed brand and the dispensed product.
- A manufacturer coupon or savings card applied to a Medicare, Medicaid, or TRICARE claim, which is illegal under the federal anti-kickback statute and can trigger a claim rejection or audit.
- A biosimilar billed under a miscellaneous unclassified HCPCS code (such as J3590) instead of its product-specific code, which can delay reimbursement or trigger a denial that gets passed to the patient as a full-price bill.
- The Stelara or Enbrel Inflation Reduction Act Maximum Fair Price not applied for a Medicare Part D claim filled on or after January 1, 2026. Every Part D plan is required to charge the negotiated price.
Frequently Asked Questions
What is the difference between a biosimilar, an interchangeable biosimilar, and a generic drug?
A generic is an exact chemical copy of a small-molecule drug like a tablet. A biosimilar is an FDA-approved biologic that is highly similar to a reference biologic, with no clinically meaningful difference in safety or effectiveness, but it is grown in living cells and can never be an exact molecular copy. An interchangeable biosimilar clears a stricter FDA bar, usually including switching studies, that lets a pharmacist substitute it for the reference product without a new prescription in most states.
Is there a biosimilar for Lantus, Humira, or Stelara in 2026?
Yes to all three. Lantus (insulin glargine) has two interchangeable biosimilars, Semglee and Rezvoglar, plus the non-interchangeable Basaglar. Humira (adalimumab) has 10 FDA-approved biosimilars, several interchangeable, including Amjevita and Hyrimoz. Stelara (ustekinumab) has eight biosimilars including the interchangeable Wezlana. None of these three biologics has a small-molecule generic because a true generic is impossible for a biologic.
Can my pharmacist switch me to a biosimilar without my doctor's approval?
Only if the biosimilar has the FDA's interchangeable designation and your state permits pharmacy-level substitution. As of 2026, 41 states plus Puerto Rico allow this; six states allow it only if it lowers your cost, and four states plus Puerto Rico require prescriber approval for every switch. Semglee, Rezvoglar, and Wezlana are all interchangeable; Basaglar is not, so switching to or from it always requires a new prescription.
How much does insulin glargine cost without insurance in 2026, and how much cheaper is the biosimilar?
Brand Lantus retails for about $274 to $400 per 30-day supply at cash price in 2026. The interchangeable biosimilars Semglee and Rezvoglar retail for roughly $74 to $150 for the same supply, a savings of 60 to 75 percent. Basaglar, a non-interchangeable follow-on insulin, runs about $150 to $258. Medicare Part D enrollees pay no more than $35 per month for any of these products under the Inflation Reduction Act's insulin cap.
How do I apply for the Sanofi Patient Connection assistance program for Lantus?
Have your prescriber's office download the two-page application at sanofipatientconnection.com, complete the patient and prescriber sections, and submit it with proof of household income, US residency, and, if applicable, documentation that you were denied Medicaid. Approval typically takes about a week, and Sanofi ships the medication directly to your prescriber's office. Household income must be at or below 400 percent of the federal poverty level.
Can I use a manufacturer savings card or coupon with Medicare or Medicaid?
No. Federal anti-kickback law bars manufacturer coupons and commercial savings cards from being used by anyone with Medicare, Medicaid, TRICARE, or VA benefits. This applies to both brand biologics and their biosimilars, including the Lilly Insulin Value Program and the Humira Complete Savings Card. Government-insured patients should instead apply for the manufacturer's income-based patient assistance program or rely on their plan's $35 insulin cap or $2,100 annual Part D out-of-pocket cap.
What if my insurance denies coverage or forces a switch between a biologic and its biosimilar?
Request the written denial notice, then file a formal appeal within 60 days with a letter of medical necessity from your prescriber. If the plan still denies coverage, ask for a peer-to-peer review, and escalate to your state Department of Insurance for external review if needed. If your plan requires you to try a biosimilar first (step therapy) and you have a clinical reason to avoid it, your prescriber can file a step-therapy override.
Does the Inflation Reduction Act's negotiated Maximum Fair Price apply to biosimilars?
The negotiated Maximum Fair Price applies to the ten Round-1 reference biologics and drugs selected by CMS, including Stelara ($4,695 for a 30-day supply, down from a $13,836 list price) and Enbrel ($2,355, down from $7,106), effective January 1, 2026. Biosimilars themselves are not separately negotiated; they compete on price against both the brand and the negotiated rate, which often makes them cheaper still for patients without Medicare.
